DARZALEX® Clinical Studies:

DARZALEX® in combination with Velcade®
(bortezomib) + melphalan + prednisone

DARZALEX® was studied in combination with Velcade®, melphalan, and prednisone (VMP) vs VMP alone in 706 patients with newly diagnosed multiple myeloma who could not receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant).

The main goal of the study was to measure the length of time patients lived without their multiple myeloma getting worse or passing away from any cause.

Another goal was to measure overall response rate, which is the percentage of patients who responded to treatment.

Clinical study results: DARZALEX® + VMP vs VMP alone

DARZALEX® in combination with VMP increased the time patients lived without their multiple myeloma getting worse.

75percent

of patients lived without their disease getting worse with
DARZALEX® + VMP (n=350) vs 60% with VMP alone (n=356).*

*At a median follow-up of 16.5 months.

More patients responded to DARZALEX® in combination with VMP vs VMP alone

9outof10-1

91% of patients responded to Velcade® + melphalan + prednisone (DVMP) (n=350) vs 74% of patients treated with VMP alone (n=356).